Emily Elswick, PA
Physician Assistant · la Fayette, GANPI 1568910461
Payments from drug & device makers
Across 277 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$927
- Novo Nordisk$479
- Lilly USA, LLC$336
- Otsuka America Pharmaceutical, Inc.$307
- Bayer$268
- Pfizer$262
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,041100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $927 |
| Novo Nordisk | 29 | $479 |
| Lilly USA, LLC | 23 | $336 |
| Otsuka America Pharmaceutical, Inc. | 15 | $307 |
| Bayer | 13 | $268 |
| Pfizer | 16 | $262 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $241 |
| AstraZeneca | 12 | $229 |
| GSK | 14 | $212 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $206 |
| Sumitomo Pharma America, Inc. | 11 | $172 |
| Amgen | 7 | $162 |
| Lundbeck LLC | 6 | $137 |
| Sanofi-aventis U.S. LLC | 6 | $118 |
| Boehringer Ingelheim | 6 | $111 |
| Astellas Pharma US Inc | 5 | $110 |
| Xeris Pharmaceuticals, Inc. | 6 | $109 |
| Merck | 5 | $83 |
| Boston Scientific | 2 | $52 |
| Amarin Pharma, Inc. | 3 | $50 |
| Exact Sciences | 3 | $46 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Nevro Corp. | 2 | $41 |
| Dexcom, Inc. | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Eisai Inc. | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Mylan Specialty L.p. | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Abbott | 1 | $19 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| Genentech USA, Inc. | 2 | $10 |
How this compares
$5,041 in reported general payments places this provider in the 90th percentile of 3,581 physician assistant providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $60,391 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $46,336 |
| EliquisApixaban | 42 | $30,806 |
| JardianceEmpagliflozin | 31 | $25,266 |
| MounjaroTirzepatide | 20 | $20,227 |
| FarxigaDapagliflozin Propanediol | 11 | $16,224 |
| GemtesaVibegron | 13 | $12,269 |
| XareltoRivaroxaban | 15 | $10,850 |
| MyrbetriqMirabegron | 18 | $9,557 |
| Repatha SureclickEvolocumab | 11 | $7,058 |
| Gabapentin | 172 | $2,686 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 81 | $2,501 |
| Duloxetine Hcl | 89 | $2,133 |
| ValacyclovirValacyclovir Hcl | 21 | $1,750 |
| Famotidine | 121 | $1,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $479 | $60,39148 claims |
| GSKTrelegy Ellipta | $212 | $46,33646 claims |
| PfizerEliquis, Paxlovid | $262 | $32,17456 claims |
| Boehringer IngelheimJardiance | $111 | $25,26631 claims |
| Lilly USA, LLCMounjaro | $336 | $20,22720 claims |
| AstraZenecaFarxiga | $229 | $16,22411 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $172 | $12,26913 claims |
| Astellas Pharma US IncMyrbetriq | $110 | $9,55718 claims |
| AbbVieSynthroid | $927 | $93217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,581 physician assistant providers in Georgia.
Other physician assistant in la Fayette
- Douglas DiruggieroCartersville$1.3M
- Jennifer CobbsAtlanta$1M
- A BrunnerStockbridge$1M
- Joseph LangshawCalhoun$887K
- Alison MoeAtlanta$410K
- Maggie SchreckAtlanta$389K
- Lisa HillMarietta$190K
- Laura BishopBrunswick$103K
- Jaime AckermanAtlanta$84K
- Richard BurrellBrunswick$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.